Last updated: February 15, 2026
What is NDC 65145-0158?
NDC 65145-0158 corresponds to Sickle Cell Disease (SCD) Treatment marketed by Global Blood Therapeutics under the brand name Oxbryta (voxelotor). Approved by the FDA in November 2019, Oxbryta is the first approved oral therapy designed to increase hemoglobin levels in patients with sickle cell disease.
Market Overview
Prevalence and Market Opportunity:
- Sickle cell disease affects approximately 100,000 Americans.
- Global prevalence surpasses 20 million, predominantly in African, Mediterranean, Middle Eastern, and Indian populations.
- No curative treatments are widely available; existing options include bone marrow transplants (limited to eligible patients) and supportive care.
Market Drivers:
- Unmet medical need for disease-modifying therapies.
- FDA approval in 2019 positions Oxbryta as a first-in-class therapy.
- Ongoing clinical trials aim to expand indications, including pediatric populations and combination therapies.
- Increasing awareness and diagnosis, propelled by improved screening initiatives.
Market Challenges:
- Price sensitivity due to healthcare reimbursement policies and socioeconomic factors.
- Competition from supportive care and emerging therapies.
- Limited access in low-income regions.
Commercial Performance to Date
- Annual sales: Estimated $175 million in 2022.
- Growth rate: Approximately 25-30% year-over-year, driven by expanding indications, new formulations, and increased diagnosis rates.
- Market penetration: Approximately 50% in eligible adult patients as of 2022.
Pricing Overview
Current Pricing (2023):
- List price: ~$37,000 - $40,000 per patient annually.
- Net price varies based on discounts, rebates, and insurance arrangements.
- The drug is usually administered orally once daily, with treatment costs comparable to other orphan drugs in rare disease categories.
Reimbursement and Insurance Coverage:
- Covered under Medicare, Medicaid, private insurers.
- Patient assistance programs mitigate out-of-pocket expenses.
- Some payers impose prior authorization and step therapy protocols.
Price Projection Analysis
Short-term (2023-2025):
- Price stability: Due to existing manufacturing costs and ongoing demand, list prices are expected to remain flat.
- Reimbursement adjustments: Slight reductions may occur through formulary negotiations.
- Market penetration: Growth in patient access expected to drive sales increases but at stabilized prices.
Medium-term (2026-2030):
- Potential price increases: 3-5% annual adjustments aligned with inflation, manufacturing improvements, or label expansions.
- Label expansion impact: Approval for pediatric use or combination therapies could increase demand, supporting sustainable pricing.
- Competitor entry: New therapies (e.g., gene therapies) may pressure pricing, possibly leading to stabilization or reduction.
Long-term (2030 and beyond):
- Market maturity: The drug may face price compression as biosimilars or generics emerge, depending on patent life extensions or new formulations.
- Therapeutic landscape shifts: Novel treatments targeting disease remission could reduce reliance on voxelotor, impacting pricing.
Competitive Landscape
| Product |
Status |
Indication |
Price (2023) |
Market Share (Est.) |
| Oxbryta |
Approved |
SCD (adults, pending pediatrics) |
~$37,000/year |
~50% |
| Adakveo (crizanlizumab) |
Approved |
SCD pain crises |
~$100,000/year |
20% |
| CRT and gene therapies |
Phase 2/3 |
SCD modifications |
Varies |
Emerging |
Note: Oxbryta remains the leading approved therapy, with ongoing trials promising additional options.
Regulatory and Policy Impact
- FDA initiatives: Advocacy for expanded indications and early diagnosis support market growth.
- Pricing regulations: Capping prices or implementing value-based reimbursement models could influence future pricing strategies.
- Orphan drug designation: Protects market exclusivity until at least 2030, delaying generic competition.
Summary and Recommendations
- The current list price of NDC 65145-0158 approximately $37,000 - $40,000 annually.
- Sales momentum is projected to grow at 20-25% annually over the next three years, contingent on expanded indications and increased patient access.
- Price stability is likely in the short term, with potential adjustments aligned with inflation and market dynamics.
- Competitive pressures from emerging therapies and policy changes could moderate future pricing.
Key Takeaways
- NDC 65145-0158 (Oxbryta) leads the market for sickle cell disease, with stable yet premium pricing.
- Market expansion depends on label extensions, especially pediatric approval.
- Pricing is influenced by payer negotiations, clinical trial outcomes, and potential competition.
- Revenue growth hinges on increasing diagnosis and treatment adoption.
- Long-term risks include pricing pressures from biosimilars or alternative therapies.
FAQs
1. What factors could lead to price reductions for NDC 65145-0158?
Introduction of biosimilars, regulatory measures capping prices, or significant market penetration by competing therapies.
2. How will indication expansion affect market value?
Expanded approvals (e.g., pediatric or combination use) can increase patient uptake, potentially elevating sales but not necessarily affecting unit price.
3. What is the typical reimbursement environment for orphan drugs like Oxbryta?
Insurance coverage is generally favorable, aided by formal approval and disease orphan status, with patient assistance programs reducing out-of-pocket costs.
4. How competitive is Oxbryta in the market?
It leads in approved SCD therapies but faces competition from other biologics and emerging gene therapies, which could alter market share.
5. When might generics or biosimilars enter the market?
Patent protections extend until at least 2030 unless extended or challenged, delaying biosimilar entry.
References
[1] FDA press release on Oxbryta approval, Nov 2019.
[2] IQVIA Sales Data, 2022.
[3] Global Blood Therapeutics Financial Reports, 2022.
[4] Medscape, 2023.
[5] Statistical World Report on Sickle Cell Disease, WHO, 2022.
